The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- Valuing and accessing medicines
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- Health Data
Valuing and accessing medicines
Ensuring value, access and uptake of innovative medicines and vaccines, now and in the future
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
Improving the UK's attractiveness for industry, research, development and manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
Building better partnerships between industry and NHS and across the Life Sciences sector
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
Building a stronger industry reputation in the UK
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
Providing international leadership and driving global policy
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
Health Data
Improving the UK's health data capability and industry's access to data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
Latest news
Science is thriving in UK regions: Government must back them
ABPI, CBI, and Birmingham Health Partners (BHP) report shines a light on life sciences in one region – the West Midlands.
Pharmaceutical industry sets out its vision for the future UK medicines regulation
Britain should work with its ‘science allies’ abroad and develop medicines regulation for emerging technologies at home to build a globally attractive life sciences sector fit for the 2020s, or it risks being left behind.
Pharmaceutical industry response to 2021 Spending Review
The Chancellor has delivered his Budget and Spending Review.
UK manufacturing holds key to unlocking Government’s domestic and global ambitions
The success of the UK’s manufacturing sector will be central to the government’s ability to deliver on its national ambitions to level up the whole country, reach Net Zero by 2050 and become a global science superpower.
Latest blogs and events
Antibiotic resistance: A global, silent pandemic that is solvable
ABPI President Ben Osborn explains the problem of antibiotic resistance and what we can do about it.
Invest and innovate to keep UK life sciences globally competitive
Richard Torbett outlines the case for investing in our sector ahead of the autumn's Comprehensive Spending Review.
ABPI & AAC ATMP Roadmap launch webinar | 9 Dec 2021
We are delighted to invite you to the launch of the brand new Accelerated Access Collaborative/ABPI Advanced Therapeutic Medicinal Products (ATMP) Roadmap.
Online Workshop on SMC: How to prepare and submit to SMC | 13-14 Dec 2021
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
Key content hubs
The COP26 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
Coronavirus (COVID-19) was officially declared a pandemic by the World Health Organization on 12 March 2020. As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to this outbreak.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
Rare diseases have a devastating impact on people’s lives: pharmaceutical companies here in the UK and around the world are working to change that – developing new medicines to give families hope for the future.
Happy Birthday @HRA_Latest!🎂Our Chief Executive @TorbettR had this to say about you:
— ABPI (@ABPI_UK) December 1, 2021
'Over the past 10 years, the Health Research Authority has established itself as a champion of ethical, high-quality research...'
Read more below #HRA10 https://t.co/ubvX6qvpRT
Resistance to #antibiotics is on the rise; this means new antibiotics need to be developed as a safety net for cancer patients of the future. Learn more here: https://t.co/GrLB7hWnj1 #TogetherForAntibiotics pic.twitter.com/fHc1uR2abK
— ABPI (@ABPI_UK) December 1, 2021
Sepsis is a reaction to serious infection, causing 48,000 UK deaths a year. Antibiotics are crucial for #sepsis but we must find new ones. With @UKSepsisTrust, we're highlighting the need for new antibiotics https://t.co/GrLB7hWnj1 #TogetherForAntibiotics @SepsisUK pic.twitter.com/Cd1SEtuLCQ
— ABPI (@ABPI_UK) November 30, 2021
‘The most important message is, yes, it’s been done at speed but no corners have been cut,’ says @runnerosborn https://t.co/2Y4GxBd7cS
— ABPI (@ABPI_UK) November 28, 2021
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/n5lbxuf1/figures-turnover-36-7bn.jpg)
![R and D Investment [3]](/media/ouqnhlry/figures-r-d-investment-5-0bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.